


Digital cardiovascular care company tenacio announces formation of International Scientific Advisory Board



Press release – Berlin/New York, 18 Jan 2022

- **tenacio appoints three highly distinguished international leaders in cardiology and cardiovascular medicine to join its Scientific Advisory Board**
- **Professor Keith AA Fox, Professor Christopher Granger, and Dr Annalisa Jenkins are recognized experts and key opinion leaders in research, development, and clinical applications of medical innovations**
- **The International Scientific Advisory Board will advise and provide clinical guidance to the company in scientific product development**

tenacio, whose mission is to improve clinical outcomes for cardiovascular patients and reduce healthcare costs through translating peer reviewed research evidence into real world practice, has established an International Scientific Advisory Board in order to support its future product development and expansion into additional clinical indications.

tenacio has developed a digital solution to address cardiovascular morbidity and mortality through precision medicine and curated treatment recommendations with atrial fibrillation as its first indication. Further product development will include the addition of new clinical indications like heart failure and coronary artery disease. The proprietary development will also include AI and machine learning technologies to predict outcomes events and optimize treatment.

The International Scientific Advisory Board will provide input and advise on the company's further development. tenacio's co-founder and CEO Dr. Georg van Husen commented: "We are thrilled and very proud to have three international top experts in cardiovascular medicine joining our Scientific Advisory Board. We are looking forward to collaborating with them closely in our future product development which aims to improve the lives of patients with cardiovascular diseases."

The members of tenacio's International Scientific Advisory Board are:

Professor Keith AA Fox, BSc MB ChB, MRCP, FRCP, FESC, FMedSci, FACC

Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK

Professor Keith AA Fox is Professor of Cardiology at the University of Edinburgh and British Heart Foundation Professor of Cardiology (Emeritus). Founding fellow of the European Society of Cardiology (ESC) and prior President of the British Cardiovascular Society and former Chair of the Scientific Program of the ESC. He is the recipient of various awards, including the Silver and Gold Medals of the European Society of Cardiology for his contributions to cardiology. He was honored by the American College of Cardiology and by the European Society of Cardiology as one of the "Legends in Cardiology". Thompson Reuters listed him as one of the top 1% of scientists as 'the World's Most Influential Scientific Minds.

Christopher B. Granger, MD, FACC, FAHA, FESC

Professor of Medicine, Division of Cardiology, Department of Medicine
Duke University Medical Center and Duke Clinical Research Institute

Dr. Christopher Granger is a Professor of Medicine in the Division of Cardiology at Duke University and immediate past Director of the Cardiac Care Unit for the Duke University Medical Center. As a clinical trialist at the Duke Clinical Research Institute, he has led some of the most important trials in cardiology. Dr. Granger is a Fellow of the American College of Cardiology, the American Heart Association, and of the European Society of Cardiology. He served for 10 years on the Board of External Experts of the National Heart, Lung and Blood Institute (NHLBI) and has co-authored more than 800 peer-reviewed manuscripts.

Annalisa Jenkins, M.B.B.S., F.R.C.P.

Dr. Annalisa Jenkins is a biopharma thought leader with over 25 years of industry experience and is an advocate for diversity and inclusion, particularly for women in science. Dr. Jenkins served as Founding CEO of Dimension Therapeutics, a rare disease AAV gene therapy company. Prior leadership roles have included the head of global research and development and executive vice president global development and medical at Merck Serono, and Head of Global Medical Affairs at Bristol Myers-Squibb. She currently services on the boards of a number of public and private life science companies. She is also a trustee for The King's Fund, medical trustee for the British Heart Foundation, a committee member of the Science Board to the U.S. Food & Drug Administration and Chair of The Court at The London School of Hygiene and Tropical Medicine.

About tenacio

- tenacio is digitizing cardiovascular care to improve outcomes and reduce cost by transforming cardiovascular disease management using state-of-the-art technology and leading-edge science to provide dynamic and individualized care for patients
- tenacio has a proprietary, validated risk prediction algorithm for stroke, mortality and bleeding and provides curated treatment recommendations for cardiovascular patients
- tenacio was founded in 2019 by Professor Ajay Lord Kakkar and Dr. Georg van Husen, MD

www.tenac.io

Press contact

Georg van Husen, co-founder & CEO

georg.van_husen@tenac.io

p +49-151-260 74154

tenac.io GmbH

Oberwallstrasse 6

10117 Berlin

Germany

tenac.io. Inc.

447 Broadway, 2nd floor

New York, NY 10013

United States

P (212)-252-2168